Walmart Sells Stake in JD.com; JD.com Shares Plunge 6%
JD Health (06618): According to the first public offering, 1 million new shares will be issued under the stock incentive plan after the initial public offering.
JD Health (06618) announced that according to the first public offering after the stock...
Brokerage Focus: Tianfeng Securities maintains a "buy" rating on JD Health (06618), pointing out that the gradual opening of online medical insurance drug purchases is expected to open up medium- to long-term growth space.
According to Tianfeng's research report, jd health (06618) achieved revenue of 28.344 billion yuan in the first half of 2024, a year-on-year increase of 4.6% from 27.1 billion yuan in the same period last year. In terms of business, the company's self-operated commodity revenue in the first half of 2024 was 23.91 billion yuan, a year-on-year increase of 3.2%; service revenue was 4.43 billion yuan, a year-on-year increase of 12.5%.
Hong Kong stocks closed (08.19) with the Hang Seng Index up 0.8%. Gold, high-speed rail concept, and automobile stocks were active. The "JD.com system" once again rose.
The Hong Kong stock market opened high and rose in the morning. Among them, the Hang Seng Technology Index performed the strongest, rising nearly 3% at one point. The gains of the three major indexes narrowed in the afternoon.
Brokerage Focus: Dongbei Securities maintains a "buy" rating on JD Health (06618), expecting the advantages of online medical insurance payment to enhance new customer acquisition.
According to a research report from Northeast Securities, JD Health (06618) achieved revenue of 28.3 billion (+4.6%) in the mid-term, of which self-operated revenue was 23.9 billion (+3.2%), and platform and service revenue was 4.4 billion (+12.5%). Gross profit was 6.7 billion (+8.06%), with a gross margin of 23.6% (+0.7pct). Non-IFRS net income was 2.64 billion (+8.5%), and net income attributable to equity holders of the parent was 2.04 billion (+30.5%). Splitting the numbers, the single Q2 achieved revenue of 15.1 billion (+14.6%), and Non-IFRS net income was 1.89 billion (+47.8%).
JD Health (06618) rose 9.09% in Hong Kong Stock Connect. The net income increased 30.48% year-on-year. China Securities Co., Ltd. predicts that the company's B2C channel has a price advantage.
Jd Health (06618) is showing a strong upward trend with a 9.09% increase to HKD 23.4 and a turnover of HKD 0.277 billion at press time, according to Jinwu Financial News. The company released its 2024 mid-term performance announcement. The financial report shows a net profit of CNY 2.037 billion attributable to the company's owners during the period, up 30.48% year-on-year, and a basic earnings per share of CNY .65, up 30% year-on-year. During the period, the revenue was CNY 28.344 billion, up 4.55% year-on-year, including commodity revenue of CNY 23.91 billion, up 3.2% year-on-year. China Securities Co.,Ltd. released a research report indicating a more price-effective system.
